The Science Behind Neologicals
Our research program is built on two decades of ligand-receptor biology, precision conjugate chemistry, and translational oncology. Below is a summary of the foundational science underpinning the Neologicals platform.
How We Build Precision Medicines
The Neologicals platform integrates three core scientific disciplines: receptor biology, medicinal chemistry, and translational pharmacology. Each program begins with deep target validation and proceeds through a rigorous, data-driven development process designed to maximize the probability of clinical success.
Receptor Biology & Target Validation
We apply multi-omic profiling — transcriptomics, proteomics, and single-cell RNA sequencing — to identify receptors with high differential expression between diseased and healthy tissue. Targets must meet stringent criteria: >10-fold overexpression in disease, low expression in critical healthy tissues, and functional internalization upon ligand binding. Validation is performed across patient-derived cell lines, primary tissue samples, and in vivo models before any ligand development begins.
Structure-Guided Ligand Engineering
Ligand design begins with computational modeling of the target receptor's binding pocket, followed by iterative rounds of synthesis and affinity testing. We employ fragment-based drug discovery, phage display, and rational design to generate lead candidates. Affinity maturation is guided by surface plasmon resonance and isothermal titration calorimetry, with selectivity confirmed against a panel of >50 structurally related receptors.
Conjugate Chemistry & Linker Engineering
Payload conjugation is performed via proprietary cleavable linker chemistry optimized for plasma stability and intracellular release kinetics. Linker design is tailored to the endosomal environment of each target cell type, ensuring payload release is triggered by the specific pH and enzymatic conditions present upon receptor-mediated internalization. Drug-to-ligand ratio is optimized to maximize potency while preserving receptor binding affinity.
Translational Pharmacology & IND-Enabling
Efficacy is evaluated in disease-relevant xenograft and syngeneic models, with pharmacokinetic/pharmacodynamic modeling used to project human dose ranges. IND-enabling packages include GLP toxicology studies in two species, CMC development for clinical-grade material, and biomarker strategy development for patient selection. Our translational team works in close collaboration with clinical advisors to design first-in-human studies with the highest probability of demonstrating proof-of-concept.
Neologicals Platform: Whitepaper Highlights
The following summarizes key findings from our foundational platform whitepaper, which establishes the scientific rationale, mechanistic evidence, and preclinical data supporting the Neologicals approach to targeted drug delivery.
The Targeting Problem in Oncology
Conventional cytotoxic agents distribute broadly throughout the body, relying on the marginally faster proliferation of tumor cells to achieve a therapeutic window. This passive approach results in dose-limiting toxicities that constrain efficacy. Antibody-drug conjugates (ADCs) have improved upon this paradigm but remain limited by large molecular size, immunogenicity, and manufacturing complexity. The Neologicals platform addresses these limitations with small-molecule ligands that combine the targeting precision of biologics with the pharmacokinetic advantages of small molecules.
Ligand-Receptor Targeting: Mechanistic Evidence
Receptor-mediated endocytosis provides a highly efficient internalization pathway for targeted conjugates. Our studies demonstrate that Neologicals conjugates achieve intracellular concentrations 40–80x higher than free drug at equivalent systemic doses in EGFR-overexpressing cell lines. Confocal microscopy and flow cytometry confirm rapid internalization (t½ < 30 min) and endosomal trafficking to the lysosomal compartment, where cleavable linker hydrolysis releases the active payload.
Preclinical Efficacy: Neologicals-001
In EGFR+ xenograft models (A431, H1975), Neologicals-001 achieved 87% tumor volume reduction at doses 5-fold below the maximum tolerated dose of the unconjugated payload. Tumor regression was durable, with no recurrence observed at 60 days post-treatment in 7/10 animals. Pharmacokinetic analysis confirmed a 3-fold improvement in tumor AUC relative to normal tissue, consistent with active receptor-mediated accumulation.
Safety & Tolerability Profile
GLP toxicology studies in rats and cynomolgus monkeys demonstrated a favorable safety profile for Neologicals-001 at doses up to 10x the projected human efficacious dose. Off-target organ toxicity was reduced by 60% compared to free payload administration at equivalent doses. No immunogenicity signal was observed over a 28-day repeat-dose study, consistent with the small-molecule nature of the ligand component.
Platform Generalizability
The Neologicals platform has been validated across three receptor targets (EGFR, CD22, folate receptor beta) and two payload classes (cytotoxic small molecules and anti-inflammatory agents), demonstrating the modular, payload-agnostic nature of the approach. Binding affinity, internalization efficiency, and intracellular release kinetics were preserved across all conjugate variants tested, supporting the platform's generalizability to new targets and indications.
Scientific Disclosures
Neologicals: A Ligand-Receptor Targeting Platform for Precision Therapeutic Delivery
Foundational platform whitepaper establishing mechanistic evidence, preclinical efficacy data, and scientific rationale for the Neologicals approach.
EGFR-Targeted Conjugate Achieves 87% Tumor Reduction in Xenograft Models with Favorable Tolerability
Preclinical data presentation for Neologicals-001 in EGFR-overexpressing solid tumor models.
Receptor-Mediated Endocytosis as a Drug Delivery Mechanism: Intracellular Concentration Advantages of Ligand-Conjugated Payloads
Mechanistic data demonstrating 40–80x intracellular concentration advantage of Neologicals conjugates vs. free drug.
Request the Full Scientific Whitepaper
Qualified investors, research partners, and clinical collaborators may request access to the complete Neologicals platform whitepaper and supporting preclinical data package.